Published in Gene Therapy Weekly, September 28th, 2006
Study 1: According to a study from the United States, genetically augmenting amyloid-beta (Abeta) 42 levels in skeletal muscle exacerbates inclusion body myositis (IBM)-like pathology and motor deficits in transgenic mice.
"The pathogenic basis of IBM, the leading muscle degenerative disease afflicting the elderly, is unknown, although the histopathological features are remarkably similar to those observed in Alzheimer disease. One leading hypothesis is that the buildup of Abeta peptide within selective skeletal muscle fibers contributes to the degenerative phenotype,"...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Gene Therapy Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.